[go: up one dir, main page]

IE832099L - Hepatitis b virus vaccine - Google Patents

Hepatitis b virus vaccine

Info

Publication number
IE832099L
IE832099L IE832099A IE209983A IE832099L IE 832099 L IE832099 L IE 832099L IE 832099 A IE832099 A IE 832099A IE 209983 A IE209983 A IE 209983A IE 832099 L IE832099 L IE 832099L
Authority
IE
Ireland
Prior art keywords
hepatitis
virus vaccine
yeast
hbsag
gene
Prior art date
Application number
IE832099A
Other versions
IE60387B1 (en
Original Assignee
Smith Kline Rit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline Rit filed Critical Smith Kline Rit
Publication of IE832099L publication Critical patent/IE832099L/en
Publication of IE60387B1 publication Critical patent/IE60387B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A DNA fragment capable of coding for HBsAg and DNA derivatives of Dane particles is fused to the region for controlling the arg3 gene of yeast and cloned in a yeast vector. The recombinant vector is employed for transforming the competent yeast cells in which the HBsAg gene is expressed. [EP0106828A2]
IE209983A 1982-09-08 1983-09-07 Hepatitis B virus vaccine IE60387B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41578982A 1982-09-08 1982-09-08

Publications (2)

Publication Number Publication Date
IE832099L true IE832099L (en) 1984-03-08
IE60387B1 IE60387B1 (en) 1994-07-13

Family

ID=23647197

Family Applications (1)

Application Number Title Priority Date Filing Date
IE209983A IE60387B1 (en) 1982-09-08 1983-09-07 Hepatitis B virus vaccine

Country Status (22)

Country Link
EP (1) EP0106828B1 (en)
JP (5) JPS5971694A (en)
KR (1) KR840006014A (en)
AT (1) ATE91718T1 (en)
AU (4) AU584580B2 (en)
CA (1) CA1222707A (en)
CY (1) CY1932A (en)
DE (1) DE3382704T2 (en)
DK (1) DK406483A (en)
ES (4) ES525439A0 (en)
FI (1) FI833205L (en)
GR (1) GR78982B (en)
HK (1) HK1004570A1 (en)
HU (1) HU196625B (en)
IE (1) IE60387B1 (en)
IL (1) IL69202A (en)
MA (1) MA19895A1 (en)
MY (1) MY102920A (en)
NO (1) NO833198L (en)
NZ (1) NZ204952A (en)
PT (1) PT77265B (en)
ZA (1) ZA836658B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936699A (en) * 1982-08-20 1984-02-28 Chemo Sero Therapeut Res Inst Shuttle vector
JPS5931799A (en) * 1982-08-16 1984-02-20 Science & Tech Agency Recombinant plasmid and preparation of transformed yeast and hepatitis virus b surface antigen using the same
WO1986007384A1 (en) * 1985-06-03 1986-12-18 Takeda Chemical Industries, Ltd. Process for preparing hapatitis b virus surface antigen p31
WO1986001534A1 (en) * 1984-09-04 1986-03-13 Takeda Chemical Industries, Ltd. Recombinant dna and its use
WO1986003411A1 (en) * 1984-12-12 1986-06-19 Takeda Chemical Industries, Ltd. Process for preparing novel protein
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
DE3677851D1 (en) * 1985-08-05 1991-04-11 Merck & Co Inc METHOD FOR INCREASING THE PRODUCTION OF RECOMBINANT PROTEIN IN YEARS OF THE GENERATION SACCHAROMYCES.
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) * 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
DE3883596T2 (en) * 1987-03-09 1994-02-17 Merck & Co Inc Purification of recombined hepatitis B surface antigen.
NZ229260A (en) * 1988-06-03 1994-02-25 Merck & Co Inc Hepatitis b virus, expression cassette for pre-s domain, host cells and
US4962656A (en) * 1989-06-30 1990-10-16 The United States Of America As Represented By The United States Department Of Energy Control and monitoring method and system for electromagnetic forming process
LT3988B (en) 1992-02-17 1996-06-25 Fermentas Biotech Inst Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof
TW340132B (en) * 1994-10-20 1998-09-11 Ibm Structure for use as an electrical interconnection means and process for preparing the same
JP4028850B2 (en) * 2004-02-04 2007-12-26 株式会社名機製作所 Mold for molding disk substrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88258I2 (en) * 1978-12-22 1994-02-03
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
GR76274B (en) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides

Also Published As

Publication number Publication date
KR840006014A (en) 1984-11-21
AU3131889A (en) 1989-07-20
ES532730A0 (en) 1985-10-16
DE3382704D1 (en) 1993-08-26
ES8506350A1 (en) 1985-07-01
ES8600939A1 (en) 1985-10-16
DK406483D0 (en) 1983-09-07
EP0106828A3 (en) 1985-11-21
CY1932A (en) 1983-09-06
JP2522825B2 (en) 1996-08-07
JPH08317796A (en) 1996-12-03
JP2702899B2 (en) 1998-01-26
NZ204952A (en) 1986-05-09
PT77265A (en) 1983-09-01
JPH02116A (en) 1990-01-05
PT77265B (en) 1986-02-04
FI833205A0 (en) 1983-09-07
ES8600938A1 (en) 1985-10-16
AU1675083A (en) 1984-03-15
CA1222707A (en) 1987-06-09
JPH02464A (en) 1990-01-05
ES532732A0 (en) 1985-10-16
ES8602120A1 (en) 1985-11-01
GR78982B (en) 1984-10-02
EP0106828A2 (en) 1984-04-25
FI833205A7 (en) 1984-03-09
FI833205L (en) 1984-03-09
AU1569288A (en) 1988-07-28
IL69202A (en) 1991-08-16
MA19895A1 (en) 1984-04-01
AU584580B2 (en) 1989-06-01
ES532731A0 (en) 1985-11-01
HU196625B (en) 1988-12-28
ATE91718T1 (en) 1993-08-15
MY102920A (en) 1993-03-31
ZA836658B (en) 1984-06-27
EP0106828B1 (en) 1993-07-21
IE60387B1 (en) 1994-07-13
ES525439A0 (en) 1985-07-01
HK1004570A1 (en) 1998-11-27
DE3382704T2 (en) 1994-02-10
DK406483A (en) 1984-03-09
JPS5971694A (en) 1984-04-23
NO833198L (en) 1984-03-09
AU9001491A (en) 1992-02-27
JPH02231084A (en) 1990-09-13

Similar Documents

Publication Publication Date Title
IE832099L (en) Hepatitis b virus vaccine
IE800991L (en) HBs Ag GENE AND PRODUCT
EP0291586A3 (en) Recombinant hepatitis b surface antigen and vaccine containing it
IL69423A0 (en) Recombinant plasmid inserted with hepatitis b virus gene,yeast transformed with said recombinant plasmid and production of hepatitis b virus surface antigen
AU8223187A (en) T cell epitopes of the hepatitis b virus nucleocapsid protein
ZA862797B (en) Hepatitis b surface antigen formed by recombinant dna techniques,vaccines,diagnostics,cell liner and methods of forming same
EP1359156A3 (en) Papilloma virus vaccine
EP0171908A3 (en) Hepatitis b virus surface antigen and production thereof
EP0101617A3 (en) Recombinant dna containing a hepatitis b virus gene, mammalian cells transformed with the cloned viral dna, and production of hepatitis b virus proteins
EP0105149A3 (en) Recombinant plasmid containing hepatitis b virus gene, yeast transformed with said recombinant plasmid, and production of hepatitis b virus surface antigen
IL90035A (en) Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants
EP0341746A3 (en) Expression of hepatitis b s and pres2 proteins in methylotrophic yeasts
EP0037723A3 (en) Expression of hormone genomic clones
EP0216564A3 (en) Infectious recombinant virus, vaccines containing said virus for feline leukemia, and methods for the production thereof
EP0068719A3 (en) Deoxyribonucleic acids, their production and use
EP0152030A3 (en) Adult t cell leukemia virus antigen polypeptide
EP0062574A3 (en) Virus protein synthesis
ES8602935A1 (en) Shuttle vector
JPS6467191A (en) Recombinant dna plasmid having integrated hepatitis b virus gene, transformed animal cell, hepatitis b viral surface antigen protein and production thereof
EP0337441A3 (en) Expression of a functional form of a herpes virus dna polymerase in yeast
ATE53235T1 (en) SYNTHESIS OF HUMAN VIRAL ANTIGENS USING YEAST.
AU8277582A (en) Method for the preparation of a dna-hybride, containing the complementary genome of the hepatitis a virus, the dna- hybride itself, the plasmic vector contain it, the specific proteins of the virus coded by the dna-hybride and vaccines containing them

Legal Events

Date Code Title Description
MM4A Patent lapsed